---
title: "The cell immunotherapy sector is partially active, with Sanyuan Gene rising over 12%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250501711.md"
description: "The cellular immunotherapy sector is somewhat active, with Sanyuan Gene rising over 12%. YKYY, Sun-Novo, JOINN, RemeGen, and HITECK also saw gains"
datetime: "2025-07-29T02:06:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250501711.md)
  - [en](https://longbridge.com/en/news/250501711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250501711.md)
generator: "portal-rs"
---

# The cell immunotherapy sector is partially active, with Sanyuan Gene rising over 12%

The cell immunotherapy sector is somewhat active, with Sanyuan Gene rising over 12%. YKYY, Sun-Novo, JOINN, RemeGen, HITECK, and others are also following suit

### Related Stocks

- [688621.CN](https://longbridge.com/en/quote/688621.CN.md)
- [603127.CN](https://longbridge.com/en/quote/603127.CN.md)
- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [300683.CN](https://longbridge.com/en/quote/300683.CN.md)
- [688658.CN](https://longbridge.com/en/quote/688658.CN.md)

## Related News & Research

- [RemeGen files board, board committee member list with disclosure responsibilities](https://longbridge.com/en/news/296803857.md)
- [VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology](https://longbridge.com/en/news/297353256.md)
- [Canadian Solar Beats on Revenue, But Investors Face Softer Q3 Setup](https://longbridge.com/en/news/297210332.md)
- [Cerenome Launches New Corporate Identity as Integrated CNS Oncology Company](https://longbridge.com/en/news/297217468.md)
- [JinkoSolar CEO Warns Solar Industry Profits Remain Under Pressure](https://longbridge.com/en/news/297063262.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**